|
1.
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
3.
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012.PubMed/NCBI
|
|
6.
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Lagos-Quintana M, Rauhut R, Yalcin A,
Meyer J, Lendeckel W and Tuschl T: Identification of
tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Zhou X, Zhao F, Wang ZN, Song YX, Chang H,
Chiang Y and Xu HM: Altered expression of miR-152 and miR-148a in
ovarian cancer is related to cell proliferation. Oncol Rep.
27:447–454. 2012.PubMed/NCBI
|
|
10.
|
Chen Y, Song YX and Wang ZN: The
microRNA-148/152 family: Multi-faceted players. Mol Cancer.
12:432013. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Tsuruta T, Kozaki K, Uesugi A, Furuta M,
Hirasawa A, Imoto I, Susumu N, Aoki D and Inazawa J: miR-152 is a
tumor suppressor microRNA that is silenced by DNA hypermethylation
in endometrial cancer. Cancer Res. 71:6450–6462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ekimler S and Sahin K: Computational
methods for microRNA target prediction. Genes (Basel). 5:671–683.
2014.PubMed/NCBI
|
|
13.
|
Thomson DW, Bracken CP and Goodall GJ:
Experimental strategies for microRNA target identification. Nucleic
Acids Res. 39:6845–6853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Braconi C, Huang N and Patel T:
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor
suppressor gene expression by interleukin-6 in human malignant
cholangiocytes. Hepatology. 51:881–890. 2010.PubMed/NCBI
|
|
15.
|
Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu
G, Zhao R, Huang H, Wang X, Qiao Y, et al: miR-152 and miR-185
co-contribute to ovarian cancer cells cisplatin sensitivity by
targeting DNMT1 directly: A novel epigenetic therapy independent of
decitabine. Oncogene. 33:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Ji W, Yang L, Yuan J, Yang L, Zhang M, Qi
D, Duan X, Xuan A, Zhang W, Lu J, et al: MicroRNA-152 targets DNA
methyltransferase 1 in NiS-transformed cells via a feedback
mechanism. Carcinogenesis. 34:446–453. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Huang J, Wang Y, Guo Y and Sun S:
Down-regulated microRNA-152 induces aberrant DNA methylation in
hepatitis B virus-related hepatocellular carcinoma by targeting DNA
methyltransferase 1. Hepatology. 52:60–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Azizi M, Teimoori-Toolabi L, Arzanani MK,
Azadmanesh K, Fard-Esfahani P and Zeinali S: MicroRNA-148b and
microRNA-152 reactivate tumor suppressor genes through suppression
of DNA methyltransferase-1 gene in pancreatic cancer cell lines.
Cancer Biol Ther. 15:419–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Theodore SC, Davis M, Zhao F, Wang H, Chen
D, Rhim J, Dean-Colomb W, Turner T, Ji W, Zeng G, et al: MicroRNA
profiling of novel African American and Caucasian prostate cancer
cell lines reveals a reciprocal regulatory relationship of miR-152
and DNA methyltranferase 1. Oncotarget. 5:3512–3525. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Wu Y, Huang A, Li T, Su X, Ding H, Li H,
Qin X, Hou L, Zhao Q, Ge X, et al: miR-152 reduces human umbilical
vein endothelial cell proliferation and migration by targeting
ADAM17. FEBS Lett. 588:2063–2069. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Su Y, Wang Y, Zhou H, Lei L and Xu L:
MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBS
Lett. 588:1983–1988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z,
Li Z and Xue Y: miR-152 functions as a tumor suppressor in
glioblastoma stem cells by targeting Krüppel-like factor 4. Cancer
Lett. 355:85–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Cheng Z, Ma R, Tan W and Zhang L: miR-152
suppresses the proliferation and invasion of NSCLC cells by
inhibiting FGF2. Exp Mol Med. 46:e1122014. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Huang S, Xie Y, Yang P, Chen P and Zhang
L: HCV core protein-induced down-regulation of microRNA-152
promoted aberrant proliferation by regulating Wnt1 in HepG2 cells.
PLoS One. 9:e817302014. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Zhai R, Kan X, Wang B, Du H, Long Y, Wu H,
Tao K, Wang G, Bao L, Li F and Zhang W: miR-152 suppresses gastric
cancer cell proliferation and motility by targeting CD151. Tumour
Biol. 35:11367–11373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Zheng X, Chopp M, Lu Y, Buller B and Jiang
F: miR-15b and miR-152 reduce glioma cell invasion and angiogenesis
via NRP-2 and MMP-3. Cancer Lett. 329:146–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao
L, Cai H, Li P, Cao Q, Ju X, et al: miR-152 controls migration and
invasive potential by targeting TGFα in prostate cancer cell lines.
Prostate. 73:1082–1089. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Dalmay T and Edwards DR: MicroRNAs and the
hallmarks of cancer. Oncogene. 25:6170–6175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Lujambio A and Esteller M: CpG island
hypermethylation of tumor suppressor microRNAs in human cancer.
Cell Cycle. 6:1455–1459. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Plass C: Cancer epigenomics. Hum Mol
Genet. 11:2479–2488. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Esteller M: CpG island hypermethylation
and tumor suppressor genes: A booming present, a brighter future.
Oncogene. 21:5427–5440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Veeck J and Esteller M: Breast cancer
epigenetics: From DNA methylation to microRNAs. J Mammary Gland
Biol Neoplasia. 15:5–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Stumpel DJ, Schotte D, Lange-Turenhout EA,
Schneider P, Seslija L, de Menezes RX, Marquez VE, Pieters R, den
Boer ML and Stam RW: Hypermethylation of specific microRNA genes in
MLL-rearranged infant acute lymphoblastic leukemia: Major matters
at a micro scale. Leukemia. 25:429–439. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Ragusa M, Majorana A, Banelli B,
Barbagallo D, Statello L, Casciano I, Guglielmino MR, Duro LR,
Scalia M, Magro G, et al: MIR152, MIR200B, and MIR338, human
positional and functional neuroblastoma candidates, are involved in
neuroblast differentiation and apoptosis. J Mol Med (Berl).
88:1041–1053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Rowland BD and Peeper DS: KLF4, p21 and
context-dependent opposing forces in cancer. Nat Rev Cancer.
6:11–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Suzuki S, Miyazaki T, Tanaka N, Sakai M,
Sano A, Inose T, Sohda M, Nakajima M, Kato H and Kuwano H:
Prognostic significance of CD151 expression in esophageal squamous
cell carcinoma with aggressive cell proliferation and invasiveness.
Ann Surg Oncol. 18:888–893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Hoefig KP and Heissmeyer V: MicroRNAs grow
up in the immune system. Curr Opin Immunol. 20:281–287. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Beaulieu AM, Bezman NA, Lee JE, Matloubian
M, Sun JC and Lanier LL: MicroRNA function in NK-cell biology.
Immunol Rev. 253:40–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Manaster I, Goldman-Wohl D, Greenfield C,
Nachmani D, Tsukerman P, Hamani Y, Yagel S and Mandelboim O:
MiRNA-mediated control of HLA-G expression and function. PLoS One.
7:e333952012. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Zhu XM, Han T, Wang XH, Li YH, Yang HG,
Luo YN, Yin GW and Yao YQ: Overexpression of miR-152 leads to
reduced expression of human leukocyte antigen-G and increased
natural killer cell mediated cytolysis in JEG-3 cells. Am J Obstet
Gynecol. 202:592.e1–592.e7. 2010. View Article : Google Scholar
|
|
46.
|
Herrmann TL, Agrawal RS, Connolly SF,
McCaffrey RL, Schlomann J and Kusner DJ: MHC Class II levels and
intracellular localization in human dendritic cells are regulated
by calmodulin kinase II. J Leukoc Biol. 82:686–699. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Liu X, Zhan Z, Xu L, Ma F, Li D, Guo Z, Li
N and Cao X: MicroRNA-148/152 impair innate response and antigen
presentation of TLR-triggered dendritic cells by targeting CaMKIIα.
J Immunol. 185:7244–7251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Nana-Sinkam SP and Croce CM: MicroRNA
dysregulation in cancer: opportunities for the development of
microRNA-based drugs. IDrugs. 13:843–846. 2010.PubMed/NCBI
|
|
49.
|
Mellor HR and Callaghan R: Resistance to
chemotherapy in cancer: a complex and integrated cellular response.
Pharmacology. 81:275–300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Harries M and Gore M: Part I: Chemotherapy
for epithelial ovarian cancer-treatment at first diagnosis. Lancet
Oncol. 3:529–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
